UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry

Davila Fajardo, R; Oldenburger, E; Ruebe, C; Lopez-Yurda, M; Pritchard-Jones, K; Bergeron, C; Graf, N; ... Oldenburger, F; + view all (2018) Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry. Pediatric Blood and Cancer , 65 (8) 10.1002/pbc.27085. Green open access

[img]
Preview
Text
Pritchard-Jones_2018 02 23 resubmitted No_boost_Stage_IR-III-WT_22-2-2018_revised_clean_version.pdf - Accepted version

Download (387kB) | Preview

Abstract

Objective: To evaluate the value of radiotherapy boost omission in patients with intermediate‐risk, stage III Wilms tumours (WT) with positive lymph nodes (LN). Methods and materials: All patients with intermediate‐risk, stage III (LN positive) WT consecutively registered in the SIOP‐WT‐2001 study were included in this analysis. Endpoints were 5‐year event‐free survival (EFS), loco‐regional control (LRC) and overall survival (OS). Results: Between June 2001 and May 2015, 2,569 patients with stage I to III WT after preoperative chemotherapy were registered in the SIOP‐WT‐2001 study. Five hundred and twenty‐three (20%) had stage III disease, of which 113 patients had stage III due to positive LN only. Of those, 101 (89%) received radiotherapy, 36 of which (36%) received, apart from flank irradiation, a boost dose to the LN positive area. Four patients (4%) did not receive any adjuvant radiotherapy. In eight patients information on radiotherapy was not available. With a median follow‐up of 71 months, no difference in 5‐year EFS (84% vs. 83%, P = 0.77) and LRC (96% vs. 97%, P = 0.91) was observed between patients receiving a radiotherapy boost and those without boost, respectively. Five‐year OS, including salvage therapy, was excellent (boost vs. no boost: 97% vs. 95%, P = 0.58). Conclusions: Outcome data demonstrate that omission of the radiotherapy boost to the loco‐regional positive lymph nodes in patients with intermediate‐risk, stage III WT who receive preoperative chemotherapy and postoperative flank irradiation (14.4 Gy) can be considered a safe approach for future SIOP protocols.

Type: Article
Title: Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/pbc.27085
Publisher version: http://doi.org/10.1002/pbc.27085
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: boost, intermediate risk, lymph node, radiotherapy, Wilms tumour
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept
URI: https://discovery.ucl.ac.uk/id/eprint/10066434
Downloads since deposit
43Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item